High-dose treatment (HDT) and autologous stem cell transplant (ASCT) in Waldenstrom’s macroglobulinemia (WM) patients (pts): A single center experience

6661 Background: An algorithm for treating WM pts (upfront or at relapse) and the optimal integration of new, active agents remain to be defined. HDT/ASCT has been used infrequently, mainly for relapsing pts. We report our HDT experience in WM pts. Patients/Results: Twenty-two pts with symptomatic WM received HDT/ASCT between 1995–2004. There were 15 men and 7 women [median age: 54 (41–75) years] with IgMκ (15), IgMλ (6) and IgAλ (1). Fifteen pts received HDT as first-line treatment at a median of 6 (3–15) months post-diagnosis. Induction treatment was DT-PACE followed by Rituxan/DT-PACE (10) and pulsed dexamethasone x1–3 followed by cyclophosphamide or CDEP (5). Eleven pts collected >10x106 CD34+ cells/Kg; 4 pts collected 7–10 x106 CD34+ cells/Kg (2 attempts). The remaining seven pts received HDT for progressive disease (PD) at a median of 5 (3–14) years post-diagnosis. Three pts collected >10x106; 2 pts collected <5x106 after 2–3 attempts. Various regimens were used for SC collection. Conditioning regim...